Abstract
In previous study, the anti-diabetic effect of Cinnamomi Cassiae extract (Cinnamon bark: Lauraceae) in a type II diabetic animal model (C57BIKsj db/db) has been reported. To explore their mechanism of action, in present study, the effect of cinnamon extract on anti-hyperglycemia and anti-hyperlipidemia was evaluated by measuring the blood glucose levels, serum insulin, and adiponectin levels, serum and hepatic lipids, PPARα mRNA expression in liver and PPARγ mRNA expression in adipose tissue, respectively. Male C57BIKs db/db mice were divided into a diabetic group and cinnamon extract treated group and examined for a period of 12 weeks (200 mg/kg, p.o). The fasting blood glucose and postprandial 2 h blood glucose levels in the cinnamon treated group were significantly lower than those in the control group (p < 0.01), whereas the serum insulin and adiponectin levels were significantly higher in the cinnamon treated group than in the control group (p < 0.05). The serum lipids and hepatic lipids were improved in the cinnamon administered group. Also the PPARα mRNA (liver) and PPARγ mRNA (adipose tissue) expression levels were increased significantly in the cinnamon treated group (p < 0.05). Our results suggest that cinnamon extract significantly increases insulin sensitivity, reduces serum, and hepatic lipids, and improves hyperglycemia and hyperlipidemia possibly by regulating the PPAR-medicated glucose and lipid metabolism.
Similar content being viewed by others
References
Chou, C. J., Haluzik, M., Gregory, C., Dietz, K. R., Vinson, C., Gavrilova, O., and Reitman, M. L., WY14, 643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem., 227, 24484–24489 (2002).
Etgen, G. J., Oldham, B. A., Johnson, W. T., Broderick, C. L., Montrose, C. R., Brozinick, J. T., Misener, E. A., Bean, J. S., Bensch, W. R., Brooks, D. A., Shuker, A. J., Rito, C. J., Mccarthy, J. R., Ardecky, R. J., Tyhonas, J. S., Dana, S. L., Bilakovics, J. M., Patemiti, J. R., Ogilivie, K. M., Liu, S., and Kauffman, R. F., A tailored therapy for the metabolic syndrome: the dual peroxisome proliferators — activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes, 51, 1083–1087 (2002).
Folch, J., Lees, M., and Sloane Stanley, G. H., A simple method for the isolation and purification of total lipids from animal tissue, J. Biol. Chem., 226, 497–509 (1957).
Frias, J. P., Yu, J. G., Kruszynska, Y. T., and Olefsky, J. M., Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care, 23, 64–69 (2000).
Fruebis, J., Tsao, T. S., Javorschi, S., Ebbets-Reed, D., Erickson, M. R., Yen, F. T., Bihain, B. E., and Lodish, H. F., Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U S A., 98, 2005–2010 (2001).
Gesler, W. W., Therapeutic landscapes: medical issues in light of the new cultural Geography. Soc. Sci. Med., 34, 735–746 (1992).
Guo, Q., Sahoo, S. P., Wang, P. R., Milot, D. P., Ippolito, M. C., Wu, M. S., Baffic, J., Biswas, C., Hernandez, M., Lam, M. H., Sharma, N., Han, W., Kelly, L. J., MacNaul, K. L., Zhou, G. Desai, R., Heck, J. V., Doebber, T. W., Berger, J. P., Moller, D. E., Sparrow, C. P., Chao, Y. S., and Wright, S. D., A Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis. Endocrinology, 145, 1640–1648 (2004).
Haban, P., Simoncic, R., Zidekova, E., and Ozdin, L., Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med. Sci. Monit., 8, 175–179 (2002).
Herz, M., Johns, D., Reviriego, J., Grossman, L. D., Godin, C., Duran, S., Hawkins F., Lochnan, H., Escobar-jimenez, F., Hardin, P. A., Konkoy, C. S., and Tan, M. H., A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther., 25, 1074–1095 (2003).
Hsueh, W. A. and Law, R., The central role of fat and effect of peroxisome proliferator activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol., 92, 3J–9J (2003).
Jackson, S. M., Parhami, F., Xi, X. P., Berliner, J. A., Hsueh, W. A., Law, R. E., and Demer, L. L., Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction, Arterioscler. Thromb. Vasc. Biol., 19, 2094–2104 (1999).
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., and Wahli, W., Peroxisome proliferatoractivated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest., 103, 1489–1498 (1999).
Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J. W., Fernandez, A. M., Reitman, M. L., Yakar, S., Stannard, B., Heron-Milhavet, M. B., and Wheeler, D., Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverse the lipotoxic state and improves glucose homeostasis. Diabetes, 52, 1770–1778 (2003).
Kimura, S., Tomita, M., Froguel, P., and Kadowoki, T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7, 941–946 (2001).
Kintscher, U. and Law, R. E., PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab., 288, 287–291 (2005).
Kitahara, Y., Miura, K., Takesue, K., Mine, T., Wada, R., Uchida, Y., lto, S., and Yagihashi, S., Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of nonobese type 2 diabetes, Metabolism, 51, 1452–1457 (2002).
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujta, T., Ezaki, O., Aizawa, S., and Kadowaki, T., PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4, 597–609 (1999).
Lee, C. H., Olson, P., and Evans, R. M., Mini review: lipid metabolism, metabolic diseases, and peroxisome proliferators-activated receptors. Endocrinology, 144, 2201–2207 (2003).
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., and Matsuzawa, Y., PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50, 2094–2099 (2001).
Miyazaki, Y., Mahankli, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., and DeFronzo, R. A., Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care, 24, 710–719 (2001).
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J., Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331, 1188–1193 (1994).
Raskin, P., Rappaport, E. B., Cole, S. T., Yan, Y., Patwardhan, R., and Freed, M. I., Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type diabetes. Diabetologia, 43, 278–284 (2000).
Reddy, J. K. and Hashimoto, T., Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr., 21, 193–230 (2001).
Ryan, A. S., Berman, D. M., Nicklas, B. J., Sinba, M., Gingerich, R. L., Meneilly, G. S., Egan, J. M., and Elahi, D., Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care, 26, 2383–2388 (2003).
Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T., and Auwerx, J., Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferators response element in the C promoter. J. Biol. Chem., 270, 19269–19276 (1995).
Spratt, K. A., A clinician’s guide to a woman’s heart. J. Am. Osteopath. Assoc., 98, 1–6 (1998).
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., and Fruchart, J. C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98, 2088–2093 (1998).
Sugden, M. C. and Holness, M. J., Potential role of peroxisome proliferator-activated activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. Diabetes, 53, S71–S81 (2004).
Tontonoz, P., Hu, E., and Spiegelman, B. M., Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipidactivated transcription factor. Cell, 79, 1147–1156 (1994).
Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F., and Flier, J. S., Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest., 99, 2416–2422 (1997).
Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S., and Kadowaki, T., The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance. J. Biol. Chem., 276, 41245–41254 (2001).
Yang, W. S., Lee, W. J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C. L., Chen, C. L., Tai, T. Y., and Chuang, L. M., Weight reducation increases plasma levels of an adiposederived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 86, 3815–3819 (2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, S.H., Choung, S.Y. Antihyperglycemic and antihyperlipidemic action of Cinnamomi Cassiae (Cinnamon bark) extract in C57BL/Ks db/db mice. Arch. Pharm. Res. 33, 325–333 (2010). https://doi.org/10.1007/s12272-010-0219-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0219-0